IngredientsGalactose is a monosaccharide sugar that differs from glucose by the orientation of the hydroxyl group on carbon 4. It belongs to the aldohexose family — six-carbon sugars carrying an aldehyde functional group — and is most biologically relevant in its D-configuration. Galactose can occur in five different forms: the open-chain form plus four anomeric cyclic forms, namely α-D-galactopyranose and β-D-galactopyranose, and α-D-galactofuranose and β-D-galactofuranose. The systematic IUPAC name is 2,3,4,5,6-pentahydroxyhexanal in its open-chain form; its CAS registry number is 59-23-4 for D-galactose (the biologically predominant enantiomer). Common synonyms include D-galactose, brain sugar, and cerebrose. Glucose, galactose, and mannose are all aldo-hexoses, which differ only in the orientation of one hydroxyl group, emphasizing the importance of stereochemistry in glycobiology.
The main dietary sources are milk and dairy products, where galactose is mainly found as a component of lactose and, to a lesser extent, in more complex carbohydrates such as oligosaccharides and polysaccharides, called glycans, which are components of milk glycoproteins and glycolipids. It is also found in many other foods, such as fruit, vegetables, cereals, legumes, nuts, and honey, where it can occur in free form, bound to polyphenols such as flavonols and anthocyanins, or as a component of glycoproteins and glycolipids. Plain natural foods (fruits, vegetables, nuts, grains, fresh meats, eggs, milk) usually contain less than 0.3 g galactose per serving. Small amounts of galactose are present in many fruits and vegetables, and considerable amounts of free galactose are present in some legumes (dried beans and peas), with bound galactose found in many food plants. Galactose, in various glycosidic linkages such as α-1,6, β-1,3 and β-1,4, and as a component of lipids, is ubiquitous in animals and plants.
Natural galactose is mostly a D-family aldose and is often found in the forms of galactan and gum, such as gelatin carrageenan and agaran, which are composed of β-D-galactose and 3,6-anhydro-α-D/L-galactose, and larch gum (arabinogalactan). Certain medications may also contain galactose as a filler.
As a dietary supplement, galactose is commercially available primarily as purified D(+)-galactose powder, typically derived from the enzymatic or acid hydrolysis of lactose obtained from dairy whey. Isolated and purified galactose appears in dietary supplement compositions alongside other monosaccharides including glucose, mannose, fucose, N-acetylgalactosamine, N-acetylglucosamine, and xylose. Such supplement forms include powdered, encapsulated, and solution preparations. In clinical investigations, oral D-galactose solutions and powders mixed into food or beverages have been the primary delivery routes. Intravenous galactose solutions have been used diagnostically and in research settings. D-galactose is also administered safely in diagnostic testing for glycogen storage disease and cirrhotic liver disease, and as sonographic contrast agents such as Levovist® (Bayer).
Galactose as an isolated compound has no independent traditional medicinal history; rather, its history is entirely intertwined with the millennia-long human relationship with lactose-containing dairy foods. Humans learned to exploit ruminants as a source of milk about 10,000 years ago. Since then, the use of domesticated ruminants as a source of milk and dairy products expanded until today, when the dairy industry has become one of the largest sectors in the modern food industry. Every consumer of dairy who digested lactose was, in effect, consuming galactose, since lactase serves to cleave dietary lactose into the monosaccharides glucose and galactose, which are then absorbed by the small intestine.
The domestication of cattle promoted milk as a food item for adult nutrition. This was only possible by two further key inventions: the concomitant domestication of lactic acid bacteria, which ferment non-digestible lactose to easily absorbed lactic acid, and the mutation to lactase persistence (LP) in adults from dairy societies. This mutation represents one of the strongest selected loci of the human genome. The allele associated with lactase persistence is thought to have emerged around 4700–4600 BC, with its frequency increasing significantly by 2000 BC. This timeline coincides with the spread of dairy farming in Europe, suggesting that the ability to digest lactose provided a selective advantage in societies reliant on milk.
Although symptoms of lactose intolerance were described by Hippocrates (460–370 BC), recognition of the extent and genetic basis of lactose intolerance is relatively recent. Until the 1960s, the prevailing assumption of Western medicine was that tolerance was the norm, and that intolerance was either the result of milk allergy, an intestinal pathogen, or psychosomatic.
Galactose as a purified substance for intentional supplementation is a modern concept, originating in 20th-century biochemistry and clinical pharmacology. Its earliest specialized clinical uses were as a liver function test and as a component of diagnostic agents, rather than as a nutritional supplement in the traditional ethnobotanical sense. No traditional herbal pharmacopoeias (e.g., Ayurveda, Traditional Chinese Medicine, European folk medicine) identify galactose in isolation as a therapeutic agent. Its closest traditional analogue is the nutritional role of human breast milk, in which lactose — and therefore galactose — is a primary energy substrate for infant brain development.
Galactose can exist in two different stereoisomeric forms: α-D-galactose and β-D-galactose. The α-form is that which is metabolized in the Leloir pathway. Conversion of the β-form of galactose to the α-form requires the enzyme galactose mutarotase, encoded by the GALM gene (also known as aldose 1-epimerase).
Upon consumption of lactose, it is hydrolyzed to glucose and galactose via the action of the intestinal enzyme complex called β-galactosidase (lactase-glycosylceramidase). Galactose is subsequently absorbed by intestinal enterocytes via the action of the same sodium (Na⁺)-dependent glucose transporter (SGLT1) that is responsible for glucose absorption. Galactose then enters the blood from intestinal enterocytes via GLUT2-mediated transport, as for glucose and fructose.
Galactose metabolism in humans is principally governed by the Leloir pathway, which converts dietary galactose into glucose-1-phosphate via the sequential action of galactokinase, galactose-1-phosphate uridylyltransferase, and UDP-galactose 4′-epimerase. Beyond its role in energy production, galactose supplies essential substrates for glycosylation of proteins and lipids.
The three steps proceed as follows: The Leloir pathway carries out the conversion of α-D-galactose to UDP-glucose via three principal enzymes: galactokinase (GALK) phosphorylates α-D-galactose to galactose-1-phosphate (Gal-1-P); galactose-1-phosphate uridyltransferase (GALT) transfers a UMP group from UDP-glucose to Gal-1-P to form UDP-galactose; and UDP-galactose-4′-epimerase (GALE) interconverts UDP-galactose and UDP-glucose, thereby completing the pathway.
Galactose metabolism takes place primarily in the cytoplasm of cells of the liver. The liver is the primary organ responsible for galactose metabolism, but other organs including the intestines and kidneys also play a role. After passing through the intestinal epithelium and entering the portal vein, galactose is transported to the liver where it is subjected to a number of enzymatic processes. Although glucose is the form of sugar stored as glycogen within cells, galactose is utilized via conversion to glucose, which can then be oxidized in glycolysis or stored as glycogen. Indeed, up to 30% of ingested galactose is incorporated into glycogen. Galactose enters glycolysis by its conversion to glucose-1-phosphate (G1P).
There are additional minor pathways of galactose metabolism in humans that do not involve all three enzymes of the classical Leloir pathway. Under normal conditions, each of these alternative pathways is responsible for the metabolism of only trace quantities of galactose. Galactose can be reduced to galactitol by NADPH-dependent aldose reductase. This latter reaction becomes significant in the context of GALT and GALK1 deficiencies that result in galactosemias. Galactose can also be oxidized to galactonate via an NAD⁺-dependent reaction; however, the enzyme in humans has yet to be characterized.
Galactose is an important constituent of complex polysaccharides, galactolipids, and other glycoconjugates of structural and functional importance. Beyond its role in energy production, galactose supplies essential substrates for glycosylation of proteins and lipids. Proteoglycans represent a major class of glycoproteins that are defined by long glycosaminoglycan (GAG) chains attached to proteins through a tetrasaccharide core consisting of glucuronic acid (GlcA)–galactose (Gal)–Gal–xylose (Xyl), attached to the hydroxyl group of serine at Ser-Gly-X-Gly amino acid motifs.
Whereas galactose addition to glycoproteins is required for neuronal functions, galactosylation is severely restricted for Asn-linked N-glycans in the brain, and genetic evidence highlights the important roles of galactose in brain functions and development. Galactosylated glycoproteins in brain sections are largely positioned in the pre- and postsynaptic membranes, and glycoproteomic analyses identified a number of these as involved in synaptic function, cell adhesion, and extracellular matrix interactions.
Both glucose and galactose have crucial roles in joining with lipids to form glycolipids and incorporating with proteins to form glycoproteins. Galactolipids are vital components of membrane tissues of plants, and galactose merging to form more complex galactocerebrosides acts as a crucial component of membrane tissues in animal muscles and nerves. Deficiencies in glycosylation are associated with the development of multiple brain disorders, such as congenital disorders of glycosylation (CDG), that include brain structural abnormalities, epilepsy and seizures, and more common disorders including schizophrenia and Alzheimer's disease.
UDP-galactose 4′-epimerase (GALE) interconverts UDP-galactose and UDP-glucose, completing the Leloir pathway and contributing to glycosylation precursors. The activated nucleotide sugar UDP-galactose is the obligate sugar donor for virtually all galactosylation reactions in mammalian cells, including assembly of glycosaminoglycans, glycolipids, and N-/O-linked glycoproteins. Galactose supplementation has been shown to rewire sugar metabolism in vitro, restoring levels of the activated sugars UDP-glucose and UDP-galactose and increasing incorporation of exogenous galactose into newly formed N-glycans.
The most firmly established clinical application of galactose is not as a dietary supplement but as a diagnostic probe of hepatic function — the Galactose Elimination Capacity (GEC) test. The galactose elimination capacity (GEC) is a clinical liver test that gives an approximate measure of the liver's maximum removal rate of galactose, Vmax, and is interpreted as a measure of metabolic liver function. Galactose is converted to galactose-1-phosphate by galactokinase, an enzyme found almost exclusively in the cytosol of hepatocytes. The GEC is performed as a single intravenous injection of galactose to a blood concentration of galactose high enough to ensure near-saturation of the galactokinase enzyme, followed by measurements of the declining blood concentration of galactose in arterialized, capillary blood samples.
The determination of the galactose elimination capacity with the method according to Tygstrup (1966) is the only test which detects the "functional hepatocyte mass" and thus constitutes a quantitative test for the metabolic function of the liver. The maximum hepatic removal rate of galactose can be estimated for the whole liver by the GEC test, which provides prognostic information on the survival probability of patients with acute liver failure, patients with cirrhosis, and patients undergoing hepatic resection.
In 25 patients with fulminant hepatic failure, the GEC was significantly higher in the five patients who survived than in the 20 patients who died. None of the other liver function tests was significantly different. All patients with a GEC below 12.8 µmol galactose/min/kg body weight died. A single-point variant (galactose single point, GSP) method uses blood galactose concentration 1 hour after oral administration of 0.5 g/kg of galactose, offering a simpler technique; significant differences in average GSP values were found between normal healthy volunteers, chronic hepatitis, cirrhosis, and hepatocellular carcinoma patients.
Evidence strength: The GEC is a well-validated, widely published clinical test with decades of human data. It is an established clinical tool, not an emerging supplement claim.
The most clinically compelling evidence for galactose supplementation comes from the rare metabolic disease PGM1-CDG (phosphoglucomutase-1 congenital disorder of glycosylation). Galactose supplementation has been shown to rewire sugar metabolism in vitro, restoring levels of UDP-glucose and UDP-galactose and increasing incorporation of exogenous galactose into newly formed N-glycans. Galactose supplementation in vitro restored endoplasmic reticulum (ER) glycan synthesis and galactosylation. Clinically, patients show improved glycosylation, endocrine function, and coagulation without adverse effects.
In a prospective pilot study, D-galactose supplementation was increased to 1.5 g/kg/day (maximum 50 g/day) in three increments over 18 weeks in nine patients with PGM1-CDG. Laboratory studies were performed before and during treatment to monitor safety and effect on serum transferrin-glycosylation, coagulation, and liver and endocrine function. Oral D-galactose supplementation was reported to be a safe and effective treatment for PGM1-CDG in this pilot study. Transferrin glycosylation and antithrombin III (ATIII) levels were useful trial endpoints. Larger, longer-duration trials are noted as ongoing.
Following 20 weeks of galactose substitution at a dose of 1 g/kg/day, significant improvement with reduced abnormal transferrin isoforms was observed. The absence of serious adverse events and generally good tolerance of increasing amounts of galactose indicated the general safety of the therapy. Transferrin glycosylation improved in all except one participant, and no further episodes of rhabdomyolysis were reported. Endocrine abnormalities improved in all patients. Liver function improved drastically, with ALT normalizing in a subset of patients and AST decreasing. Coagulation parameters improved or normalized.
A further study reported clinical and laboratory features in 11 patients with PGM1-CDG before and after treatment with galactose. In the majority of neonatal patients, the D-galactose supplementation improved some of the most frequent symptoms, including hypoglycemic episodes, liver disease, endocrine dysfunction, and growth delay. Improvement was also seen in muscle symptoms in 3 patients after D-galactose treatment.
D-galactose at 1.0–2.5 g/kg/day (max 50 grams) has been demonstrated to improve hypoglycemia, coagulopathy, and endocrinopathy in PGM1-CDG. Galactose has also been shown to improve the endocrinopathy and coagulopathy in TMEM165-CDG and SLC39A8-CDG.
Improvement of transferrin glycosylation was also observed in untreated individuals in one study. Independently, a published study underscored positive effects on clinical presentation — namely seizure control — as well as biochemical abnormalities, further strengthening the case for galactose supplementation as a treatment for SLC35A2-CDG.
Besides PGM1-CDG, galactose supplementation showed promising results in SLC35A2-CDG, SLC39A8-CDG, and TMEM165-CDG.
Evidence strength: Moderate for PGM1-CDG specifically; evidence is based on small prospective pilot studies and case series (largest involving 11 patients). Results are clinically meaningful but larger controlled trials are still needed. Evidence for other CDG subtypes remains at the level of single cases or very small series.
A hypothesis proposed that a circulating permeability factor (FSPF) responsible for podocyte injury in primary FSGS binds to galactose residues, and that supplemental galactose might saturate or neutralize this factor. The interaction between FSPF and glomeruli may depend on FSPF binding to galactose, and the FSPF-galactose complex may be susceptible to uptake by galactose-binding proteins and to catabolism.
The FONT (Novel Therapies for Resistant FSGS) Phase II clinical trial (NCT00814255) was designed to assess the efficacy of adalimumab and galactose compared to standard medical therapy comprising lisinopril, losartan, and atorvastatin. Key eligibility criteria were biopsy-confirmed primary FSGS or documentation of a causative genetic mutation, urine protein:creatinine ratio >1.0 g/g, and estimated glomerular filtration rate (eGFR) >40 ml/min/1.73 m². The experimental treatments were administered for 26 weeks.
A pilot study involving galactose supplementation in seven patients with steroid-resistant nephrotic syndrome (SRNS) demonstrated a significant reduction in permeability factor activity following galactose administration, yet no improvement in proteinuria was observed. Additionally, the Phase II clinical trial (NCT00814255) in patients with refractory FSGS reported that only two of seven participants in the galactose group achieved the primary endpoint.
Evidence strength: Weak to modest. The Phase II FONT trial demonstrated a biological signal (reduced FSPF activity) but failed to demonstrate clinically meaningful improvement in proteinuria or disease progression in most participants. Galactose is not an established treatment for FSGS.
High-dose systemic D-galactose in rodents has been widely used as an experimental tool to simulate accelerated brain aging. Rodents exposed to D-galactose are held to recapitulate a number of features of aging, including neurobehavioral and neurochemical changes. However, results from animal studies are often inconsistent. Chronic systemic administration of D-galactose was used to artificially create brain senescence in animal models and established to be beneficial for studies of anti-aging therapeutic interventions.
A systematic review and meta-analysis published in PLOS ONE (2017) apprised this model across the published literature. This meta-analysis indicates the inconsistency and heterogeneity of the included publications, perhaps due to modest reported study quality or other factors influencing performance of the model which have not been identified. These shortcomings should be addressed before efficacy in D-galactose models can be used as a signal to proceed with human clinical trials.
Importantly, in these rodent aging models, high-dose D-galactose is administered to induce pathology (oxidative stress, inflammation, cognitive decline), not to treat or prevent it. When D-galactose accumulates in the body, it undergoes oxidation by galactose oxidase, forming aldehydes and hydrogen peroxide (H₂O₂). This oxidative mechanism is the basis of the aging model — it is the opposite of a proposed benefit of galactose supplementation. The use of D-galactose as a pro-aging agent in rodents is therefore a distinct line of research from any supplementation rationale in humans.
The primary interest in galactose supplementation for brain health relates to its potential as an alternative energy source for brain cells, which is relevant for age-related cognitive changes. However, controlled human clinical trial evidence for this application is currently absent from the peer-reviewed literature.
Evidence strength: Preclinical/animal only for the brain aging model hypothesis; no human clinical trials have evaluated therapeutic galactose supplementation for cognitive decline or neurodegeneration. The animal model data themselves are heterogeneous and inconsistent according to meta-analysis.
Paradoxically, given that galactosemia requires strict galactose restriction, some researchers have explored whether trace supplementation could address the over-restriction hypothesis. Classical galactosemia is caused by severe galactose-1-phosphate uridyltransferase deficiency. Despite life-long galactose restriction, many patients experience long-term complications. Intoxication by galactose and its metabolites as well as over-restriction of galactose may contribute to the pathophysiology. Researchers provided temporary low-dose galactose supplements to patients.
Twenty-six patients (mean age 8.6 ± 1.9 years) were enrolled. Thirteen were provided with 300 mg of galactose/day followed by 500 mg for 2 weeks each (13 patient controls). No clinical changes were observed with the intervention.
Evidence strength: Very preliminary. A single small pilot study showed no clinically discernible effect at low doses. This remains an area of hypothesis generation only.
D-galactose is administered safely in diagnostic testing for both glycogen storage disease and cirrhotic liver disease, and as sonographic contrast agents such as Levovist® (Bayer). Levovist (galactose-based microparticles) was one of the first clinically approved ultrasound contrast agents, exploiting galactose microparticles to generate transient microbubbles. This represents a regulated, well-characterized clinical application distinct from nutritional supplementation.
The hexose galactose is almost exclusively metabolized in the liver, a property that is utilized in the galactose elimination capacity test (GEC). The liver's enzymatic capacity for galactose phosphorylation via galactokinase makes it the central organ for galactose homeostasis. The GEC reflects total functional hepatocyte mass and is a sensitive marker for conditions including cirrhosis, fulminant hepatic failure, and post-surgical liver reserve.
The body utilizes galactose for more than just energy; it is a component in the synthesis of glycoproteins and glycolipids. These molecules are part of the structure of cell membranes and play a role in cell-to-cell communication and immune responses. The nervous system relies on these galactose-containing compounds for the formation and maintenance of its tissues. The discovery of galactosylated N-glycoproteins and their relative confinement to synapses provides novel insights into the unusual and specific nature of protein glycosylation in the brain.
Proteoglycans are defined by long glycosaminoglycan (GAG) chains attached to proteins through a tetrasaccharide core containing galactose. Proteoglycan GAGs can be further classified by composition and sulfation; common GAGs include heparan sulfate, chondroitin sulfate, and dermatan sulfate. Glycosaminoglycans are crucial to the formation of the glycocalyx, an essential structure for the maintenance of the cell membrane that also functions as a reservoir for sequestered growth factors.
Galactose's role in N-linked and O-linked glycosylation directly affects the function of clotting factors and hormones. Evidence from PGM1-CDG treatment studies demonstrates that normalizing galactose availability can restore coagulation and endocrine parameters. Endocrine abnormalities improved in all patients, and liver function improved drastically, with ALT normalizing in a subset and AST decreasing. Coagulation parameters improved or normalized.
Galactose has been investigated in primary FSGS due to the proposed role of a galactose-binding circulating permeability factor. The relationship is mechanistically plausible but clinically unproven at the level needed for therapeutic recommendation, as discussed in Section 4.3.
Side effects from the test substance galactose are not to be expected in individuals with intact galactose metabolism, based on decades of clinical use in hepatic diagnostics. For the general population, galactose supplements are considered safe when used appropriately. Excessive intake may lead to gastrointestinal side effects like bloating, abdominal pain, or diarrhea. Comprehensive, long-term safety studies in large human populations are limited.
Inherited defects in the Leloir pathway give rise to distinct forms of galactosaemia: GALT deficiency (classic galactosaemia), galactokinase deficiency (type II), and GALE deficiency (type III). Individuals with galactosemia lack a functional enzyme needed to break down galactose, causing a toxic accumulation in the blood. This buildup can lead to severe health issues like liver damage, cognitive delays, and cataracts, requiring strict avoidance of all galactose. A galactose-restricted diet free of lactose is lifesaving in patients with galactose-1-phosphate uridyltransferase (GALT) deficiency.
High-dose exposure to D-galactose (120 mg/kg) can cause reduced sperm concentration and sperm motility in rodents and has been extensively used as an aging model when administered subcutaneously. These findings are from animal studies using supraphysiological doses delivered systemically; their direct relevance to human oral supplementation at physiological doses is uncertain but warrants attention.
Two studies have suggested a possible link between galactose in milk and ovarian cancer. Other studies show no correlation, even in the presence of defective galactose metabolism. A 2006 pooled analysis of 12 cohort studies done by Harvard School of Public Health found no association of intake of dairy foods with ovarian cancer and a statistically insignificant increase in risk of ovarian cancer at intakes of lactose >30 g/day. This relationship remains unresolved and should not be interpreted as causal.
The most obvious sources of galactose are milk and all dairy products. Beans, peas, and a few vegetables also often contain enough galactose to cause problems for patients with galactosemia. Certain medications may contain galactose as a filler, making dietary management complex for those requiring restriction.
There are no classic drug–drug interactions with galactose itself. The main risk is confounding — for example, adding galactose while starting other therapies, making it hard to attribute observed changes. In the CDG context, for CDG care in children, clinicians often keep the overall diet stable and adjust only the galactose addition.
The body of evidence supporting galactose supplementation for most proposed applications is characterized by small sample sizes, open-label pilot designs, and limited placebo controls. Most reports are open-label pilots, case series, or mechanistic studies with careful laboratory endpoints. The strongest clinical evidence exists for its use in diagnosing hepatic functional reserve (GEC test, well-validated over decades) and for treating PGM1-CDG (pilot-level evidence, clinically promising). Evidence for FSGS is Phase II and largely negative on primary clinical endpoints. Evidence for cognitive aging in humans is absent. No regulatory body (FDA, EMA, or equivalent) has approved galactose as a dietary supplement for any health claim.
Health conditions that Galactose may help support.
Body systems that Galactose may help support.
Go back